By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PTC Therapeutics, Inc. 

100 Corporate Court

South Plainfield  New Jersey  07080-2449  U.S.A.
Phone: 908-222-7000 Fax: 908-222-7231


Drug Discovery

Company News
PTC Therapeutics (PTCT) Completes Acquisition Of Emflaza For The Treatment Of Duchenne Muscular Dystrophy In The U.S. 4/21/2017 6:20:43 AM
PTC Therapeutics (PTCT) Announces Departure Of Chief Financial Officer, Shane Kovacs 4/11/2017 8:44:47 AM
Sanders, Cummings Demand PTC Therapeutics (PTCT) Chief Peltz Spell Out Price For Controversial DMD Drug 3/23/2017 6:39:47 AM
PTC Therapeutics (PTCT) Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update 3/16/2017 11:28:53 AM
PTC Therapeutics (PTCT) Buys Marathon Pharma's Controversial $89,000-Per-Year DMD Drug for $190 Million 3/16/2017 6:38:41 AM
PTC Therapeutics (PTCT) Announces Timing Change For Fourth Quarter And Year End 2016 Financial Results 3/13/2017 9:07:39 AM
PTC Therapeutics (PTCT) Announces FDA Acknowledgment Of New Drug Application Filing For Translarna For The Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy 3/6/2017 8:51:47 AM
PTC Therapeutics (PTCT) Ditches Cystic Fibrosis Drug After Trial Failure 3/2/2017 7:03:57 AM
PTC Therapeutics (PTCT) Announces Results From Pivotal Phase III Clinical Trial Of Ataluren In Patients Living With Nonsense Mutation Cystic Fibrosis 3/2/2017 6:33:39 AM
PTC Therapeutics (PTCT) Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2/22/2017 7:24:33 AM